Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05164094 · ClinicalTrials.gov registry record · Phase 1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

A Phase 1 study of Epstein-Barr Virus Infection, sponsored by ModernaTX.

Active
Registry status
Phase 1
Development phase
867
Enrollment target
20
Study locations

NCT05164094 is a Phase 1 study of Epstein-Barr Virus Infection that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 867 participants, above the 340-participant average among 6 other Epstein-Barr Virus Infection trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05164094, a Phase 1 study of Epstein-Barr Virus Infection, is active but no longer recruiting, sponsored by ModernaTX.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
867 participants
Enrollment target
20
Study locations

Study Summary

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.

Conditions Studied

Epstein-Barr Virus Infection

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL mRNA-1189

Study Locations (20)

California

  • Smart Cures Clinical Research - Anaheim
  • Benchmark Research - Colton - HyperCore - PPDS - Colton
  • Fomat Medical Research - Oxnard
  • Center For Clinical Trials LLC -Paramount - Paramount
  • Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS - Riverside
  • Peninsula Research Associates - Headlands Research - PPDS - Rolling Hills
  • Velocity Clinical Research - Banning - PPDS - San Bernardino
  • Acclaim Clinical Research - San Diego
  • California Research Foundation - 4180 Ruffin Rd - San Diego
  • Orange County Research Center - Tustin

Georgia

  • iResearch Savannah - CenExel - PPDS - Savannah
  • Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Savannah
  • Clinical Research Atlanta - Headlands - PPDS - Stockbridge

Florida

  • Research Centers of America - ERG - Hollywood
  • Jacksonville Center For Clinical Research - ERN - PPDS - Jacksonville

Illinois

  • Olivo Medical and Wellness Center - Chicago
  • DM Clinical Research - River Forest

Alabama

  • Medical Affiliated Research Institute - Huntsville

Arizona

  • Alliance for Multispecialty Research, LLC - Tempe

Idaho

  • Velocity Clinical Research - Meridian

Trial Details

FieldValue
Enrollment Target 867 participants
Start Date 2021-12-28
Est. Completion 2026-10-05
Phase Phase 1

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05164094

The ClinicalTrials.gov registry entry for NCT05164094 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 867 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 340-participant average among 6 other Epstein-Barr Virus Infection trials with a reported enrollment target (155% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Epstein-Barr Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05164094 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Georgia, Florida.

Frequently Asked Questions

What is clinical trial NCT05164094 about?

NCT05164094 is a clinical study titled "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults". The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main...

What is the current status of trial NCT05164094?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 867 participants. The study started on 2021-12-28. Estimated completion is 2026-10-05.

What conditions does trial NCT05164094 study?

This clinical trial studies the following conditions: Epstein-Barr Virus Infection.

What interventions are being tested in trial NCT05164094?

The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1189 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05164094?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05164094 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Epstein-Barr Virus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Epstein-Barr Virus Infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.